LUPKYNIS US Registry Trial

Overview

About this study

This observational study is a registry designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Lupus nephritis (LN) confirmed by biopsy

- Initiating or have initiated treatment with commercial LUPKYNIS as per US approved
Prescribing Information (PI).

- Written informed consent.

Exclusion Criteria:

- Off-label use (Use of LUPKYNIS outside of the FDA-approved US Prescribing Information).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla. Mayo Clinic principal investigator Vikas Majithia, M.D., M.P.H.	Closed for enrollment	Contact information: Vikas Majithia 9049532062 majithia.vikas@mayo.edu

Mayo Clinic Location

Status

Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Vikas Majithia, M.D., M.P.H.

Closed for enrollment

Contact information:

Vikas Majithia

9049532062

majithia.vikas@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials